Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-α Activation Make the Difference?
- 2 September 2008
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 52 (10), 882-884
- https://doi.org/10.1016/j.jacc.2008.06.012
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in MiceJournal of the American College of Cardiology, 2008
- Long-term Risk of Cardiovascular Events With RosiglitazoneJama-Journal Of The American Medical Association, 2007
- Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes MellitusJama-Journal Of The American Medical Association, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Going nuclear in metabolic and cardiovascular diseaseJCI Insight, 2006
- Therapeutic Roles of Peroxisome Proliferator–Activated Receptor AgonistsDiabetes, 2005
- A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and DyslipidemiaDiabetes Care, 2005
- Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytesBioinformatics, 2004
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000